SPONSOR
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Total Trials
12
Recruiting
12
Phases
Phase 2, Phase 1, Phase 2, Phase 3, EARLY_Phase 1
Conditions studied: Gastric CancerGastroesophageal-junction CancerColorectal CancerPancreatic CancerHepatocellular CarcinomaLiver TransplantationHepatobiliary SurgeryProphylactic AntibioticsSystemic Lupus Erythematosus (SLE)Type 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is a clinical research sponsor with 12 registered studies on ClinicalTrials.gov, of which 12 are actively recruiting participants. Research covers conditions including Gastric Cancer, Gastroesophageal-junction Cancer, Colorectal Cancer, Pancreatic Cancer.
The trial portfolio spans Phase 2, Phase 1, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
How many clinical trials has The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School sponsored?
ClinicalMetric currently tracks 12 clinical trials sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, of which 12 are actively recruiting participants. These trials cover conditions including Gastric Cancer, Gastroesophageal-junction Cancer, Colorectal Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School research focus on?
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School clinical trials span Gastric Cancer, Gastroesophageal-junction Cancer, Colorectal Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School clinical trial?
To participate in a The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials with current recruitment status updated daily.
Clinical Trials by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT05687357 Phase 2
Recruiting
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
Gastric Cancer
NCT07353645 Phase 1, Phase 2
Recruiting
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
Colorectal Cancer
NCT06791148 Phase 2
Recruiting
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
Gastric Cancer
NCT04595864 Phase 3
Recruiting
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
Hepatocellular Carcinoma
NCT07620223
Recruiting
Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings
Hepatobiliary Surgery
NCT06946485 EARLY_Phase 1
Recruiting
Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
NCT07023172
Recruiting
Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets
Type 2 Diabetes
NCT06662006 Phase 2
Recruiting
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
Advanced Metastatic Pancreatic Cancer
NCT07603128
Recruiting
Multicenter Validation of a Risk Prediction Model for MDRGNB Infection
Infection
NCT06561906
Recruiting
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
Alzheimer Disease, Late Onset
NCT07612163
Recruiting
Clinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients
Bacterial Infections
NCT06162767
Recruiting
Cancer of Esophagogastric Junction: Optimized Sweet Versus Ivor-Lewis
Esophagogastric Junction Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology